Out-of-office blood pressure: from measurement to control by Baguet, Jean-Philippe
© 2012 Baguet, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Integrated Blood Pressure Control 2012:5 27–34
Integrated Blood Pressure Control
Out-of-office blood pressure: from measurement 
to control
Jean-Philippe Baguet1,2
1Department of Cardiology, 
University Hospital, 2Bioclinic 
Radiopharmaceutics Laboratory, 
INSERM U1039, Joseph Fourier 
University, Grenoble, France
Correspondence: Jean-Philippe Baguet 
Clinique de Cardiologie, CHU de 
Grenoble, BP 217 38043, Grenoble, 
Cedex 09, France 
Tel +33 4 7676 8480 
Fax +33 4 7676 5559 
Email jpbaguet@chu-grenoble.fr
Abstract: Hypertension is an important risk factor for the development of cardiovascular 
  disease, and is a major cause of morbidity and mortality worldwide. Traditionally, hyperten-
sion diagnosis and treatment and clinical evaluations of antihypertensive efficacy have been 
based on office blood pressure (BP) measurements; however, there is increasing evidence that 
office measures may provide inadequate or misleading estimates of a patient’s true BP status 
and level of cardiovascular risk. The introduction, and endorsement by treatment guidelines, 
of 24-hour ambulatory BP monitoring and self (or home) BP monitoring has facilitated more 
reliable and reproducible estimations of true BP, including the identification of white-coat and 
masked hypertension, and evaluation of BP variability. In addition, ambulatory BP monitor-
ing enables accurate assessment of treatment effectiveness over 24 hours and both ambulatory 
and self BP monitoring may lead to better tailoring of therapy according to BP profile and 
concomitant   disease. This review describes the clinical benefits and limitations of out-of-office 
assessments and their applications for effective management of hypertension and attainment 
of BP control.
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Introduction
The association of high blood pressure (BP) and the occurrence of vascular events 
such as stroke and coronary artery disease is well known.1,2 The majority of epi-
demiological studies establishing a relationship between cardiovascular (CV) and 
cerebrovascular morbidity and mortality and BP have been based on clinical BP 
measurement. In addition, most therapeutic trials of hypertension have used   lowering 
clinical BP as the primary endpoint, as a surrogate for reduced CV or renal disease. 
However, the occurrence of hypertension-related target organ damage and CV 
or cerebrovascular events have been shown to be more correlated with 24-hour 
ambulatory and self-measured BP values than to office BP measurements.3–7 This 
is mainly due to the high variability of BP from one cycle to the next and during 
the nycthemeral period.
Ambulatory BP monitoring (ABPM) and self (or home) BP monitoring (SBPM) 
techniques were developed to provide a more standardized and reliable estimation 
of true BP and CV risk. The diagnostic and prognostic value of both methods is 
increasingly recognized by treatment guidelines; for example, the recent updates 
to the United Kingdom National Institute of Clinical Excellence guidelines include 
a recommendation of ABPM or SBPM for diagnosis of hypertension in patients 
with clinic BP of .140/90 mmHg and for evaluation of treatment efficacy.8 
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Here, the   clinical benefits and limitations of each method 
and their applications for the management of hypertension 
are reviewed.
24-hour ABPM
Initially reserved for research purposes, ABPM has become 
a widely used clinical tool. It is the noninvasive method of 
BP measurement that provides the most detailed informa-
tion for a given patient over a 24-hour period, including 
circadian fluctuations and differences between daytime and 
nighttime BP (Figure 1). ABPM is more reproducible than 
office measurements,9 and despite being more restrictive for 
patients than self-measuring devices, tolerance of ABPM is 
good and has no detrimental effect on sleep quality.10
To be effective, ABPM devices must be indepen-
dently validated according to international protocols.11–13 
  Different sampling intervals can be used, although it is best 
not to exceed 20–30 minutes to avoid incorrect estimates 
of 24-hour, daytime, or nighttime BP values.14 Based on 
cross-sectional population studies, the upper   normality 
limit for BP (ie, the value corresponding to an office 
BP of .140/90 mmHg) approximately corresponds to mean 
24-hour BP values of 125–130/80 mmHg and daytime BP 
values of 130–135/85 mmHg.8,15,16
ABPM for identifying white-coat  
and masked hypertension
Advantages of ABPM include identification of patients 
with white-coat or masked hypertension. The former is 
characterized by a persistently high office BP but normal 
ambulatory BP. The prevalence of white-coat hypertension is 
high, presenting in about 15% of the general population and 
accounting for a noticeable proportion (one-third or more) of 
individuals in whom hypertension is diagnosed.15 White-coat 
hypertension appears to be more common in women, the 
elderly, and patients with mild hypertension.17 These patients 
would normally receive antihypertensive treatment on the 
basis of office BP measurement, thus identification is impor-
tant as patients with white-coat hypertension may respond 
differently to antihypertensive drugs and may develop more 
side-effects from treatment.18 Most data indicate white-coat 
hypertension represents a lower CV risk than sustained hyper-
tension (ie, found by both office and ambulatory recordings); 
however, conflicting evidence regarding the prevalence of 
target organ damage and susceptibility to future hypertension 
has led to uncertainty as to whether white-coat hypertension 
represents a truly innocent phenomenon.19–22 Clinical trials 
are needed to ascertain whether treatment of patients with 
white-coat hypertension reduces adverse clinical events.
Masked hypertension (also known as reverse white-coat 
hypertension, white-coat normotension, or isolated ambula-
tory hypertension) is defined as normal BP values in the office 
but elevated BP outside the office (using ABPM or SBPM). 
Its prevalence varies according to the studied population, 
but is approximately 15%.22 Cross-sectional studies have 
shown that masked hypertension is associated with increased 
left ventricular mass, carotid intimal medial thickness, and 
  arterial stiffness.23–25 Epidemiological prospective studies 
suggest that masked hypertension is an independent and 
strong predictor of CV morbidity and mortality.22,26–30 
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Figure 1 Twenty-four-hour ambulatory blood pressure measurement showing a fall in blood pressure during a siesta and at night.
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Factors that can raise ambulatory BP increase the likelihood 
of having masked hypertension.31
ABPM and Cv outcomes
Several studies have demonstrated the prognostic benefit of 
ABPM, with evidence that 24-hour daytime or nighttime aver-
age BP val  ues correlate with subclinical organ damage more 
closely than office values.7,32–34 The Ohasama study – the first 
study to address the prognostic value of ABPM – reported a 
greater association between ambulatory BP and CV   mortality 
than office BP.33 Clement et al showed that for the same clini-
cal systolic BP, CV prognosis was worsened (incidence of CV 
events multiplied by two to three) when 24-hour systolic BP 
was $135 mmHg.7 In the SYST-EUR (Systolic Hypertension 
in Europe) study, ambulatory but not clinical BP was shown 
to predict CV mortality during follow-up; higher 24-hour BP 
was associated with total, cardiac, and cerebrovascular events 
in untreated hypertensives.34
ABPM for evaluating pharmacological 
treatment of hypertension
To reduce CV risk of patients with hypertension, antihyperten-
sive agents should provide effective, sustained, and smooth BP 
reduction throughout the 24-hour dosing period.35–37 ABPM 
has drastically improved the ability to assess the efficacy of 
antihypertensive drugs in both clinical trials and medical 
practice.38–42 Greater reproducibility, lack of placebo effect, 
and absence of an alerting-dependent BP response make 
ABPM the ideal tool to quantify the antihypertensive effect 
of new drugs in clinical trials, as well as drug combinations 
or nonpharmacological measures.39 It also makes it possible 
to compare the ability of different drugs or doses to provide 
smooth and consistent reductions in BP using indices such as 
trough-to-peak ratio and smoothness index.37,43
ABPM for personalizing treatment 
according to BP profile
Morning BP
There is a steep rise in BP between sleeping and waking. This 
has clinical importance since a morning peak is related to an 
increased incidence of coronary events and stroke, notably 
among elderly patients.44,45 It is therefore important to ensure 
antihypertensive therapies provide coverage throughout the 
24-hour dosing period, thereby blunting the early morning 
surge in BP.46 ABPM allows assessment of antihypertensive 
efficacy during windows of the 24-hour cycle, including the 
early morning period.
Nighttime BP and dipping status
Nighttime BP is considered to be a better predictor of CV 
risk and mortality than daytime BP.4,34,47,48 The normal 
circadian rhythm of BP includes a nocturnal decrease of 
15%–25% in BP compared to daytime values.46 ABPM is 
beneficial in determining dipper status, notably the deleteri-
ous effect of nondipping whereby patients with hypertension 
demonstrate a nocturnal BP fall of ,10% compared with 
daytime BP. Loss of nocturnal decline in BP has been associ-
ated with increased risk of cardiac, renal, and vascular target 
organ damage compared with normotensive patients.48–50 
Verdecchia et al noted a risk of CV events 2.5 times higher 
in nondipper hypertensives,49 whilst Kario et al showed that 
nondipping and extreme dipping (nocturnal BP fall of .20%) 
were associated with an increased risk of cerebrovascu-
lar damage (ie, lacunae and periventricular white matter 
hyperintensity).50 Studies have demonstrated that evening 
administration of long-acting antihypertensives results in 
greater reduction of nighttime BP than morning administra-
tion, without loss of 24-hour efficacy.51–53 For example, the 
Spanish MAPEC (Ambulatory Blood Pressure Monitoring 
for Prediction of Cardiovascular Events) prospective study 
demonstrated that bedtime administration of hypertension 
therapies exerted significantly better BP control and CV 
risk reduction than conventional morning administration.51 
Subjects taking medication at bedtime showed significantly 
lower mean sleeptime BP and a significantly reduced preva-
lence of nondipping (34% versus 62%; P , 0.001) than 
subjects taking medication upon awakening.51 In addition, 
evening dosing was associated with a higher prevalence of 
controlled ambulatory BP (62% versus 53%; P , 0.001) 
and a significantly lower risk of total CV disease events.51 
Timing treatment administration to reflect the circadian 
variation of the renin-angiotensin system is therefore an 
effective means of optimizing treatment of patients with 
essential hypertension.
BP variability
ABPM provides a powerful tool for establishing and ana-
lyzing BP variability, which is increased in patients with 
hypertension and associated with target organ damage and 
CV risk.25,54,55 Long-acting antihypertensives that provide 
consistent and durable BP reduction may be beneficial in 
reducing BP variability;56 however, accurate analysis of vari-
ability is still in the research phase and this parameter cannot 
yet be used to classify patient risk and assess the efficacy of 
antihypertensive treatment.
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ABPM for specific clinical conditions
Obstructive sleep apnea (OSA)
OSA and hypertension are linked in a dose-response 
  fashion.57 Many mechanisms are responsible for OSA-related 
hypertension, notably sympathetic hyperactivity.58 Although 
more than half of apneic patients are hypertensive, it is well 
established that hypertension is largely underdiagnosed 
in OSA patients.59 Hypertension must be systematically 
looked for and treated in apneic subjects, particularly if it 
is predominantly nocturnal, diastolic, refractory, or linked 
to a nondipper profile.60 ABPM enables detection of hyper-
tension in OSA patients,60 and is useful for evaluating the 
efficacy of antihypertensive drugs. For example, a recent 
study of untreated hypertensive OSA patients demonstrated 
that valsartan induced a four-fold greater decrease in mean 
24-hour BP than continuous positive airway pressure.61 
However, additional studies are needed to establish the 
effect of antihypertensive treatment on clinical outcomes 
in OSA patients.
Diabetes and metabolic syndrome
Diabetes and metabolic syndrome are recognized as CV risk 
factors.15 Patients with hypertension have up to three times 
higher risk of developing diabetes than normotensives,62 and 
the prevalence of nondipping is high.63–65 The coexistence of 
diabetes and hypertension has been linked to a substantial 
increased risk of renal and other organ damage, leading to a 
higher incidence of stroke and CV events.15 ABPM enables 
early detection of hypertension in diabetic and metabolic syn-
drome patients, facilitating early treatment and risk   reduction. 
In type 1 diabetic patients, ABPM with position analysis 
may be used to determine different patterns in relation to the 
disease duration and the presence of microangiopathy.66
Heart failure
In most cases of systolic left ventricular dysfunction, BP 
is low. This is not without consequence as a systolic BP 
lower than 105 mmHg over 24 hours may be an excess 
mortality factor.67 The prevalence of nondipping in heart 
failure patients is high (approximately 80%),68 necessitating 
detection and monitoring by ABPM and better treatment of 
hemodynamic parameters.
SBPM
SBPM is becoming increasingly popular among patients and 
gaining greater acceptance among physicians as a valuable 
adjunct to office monitoring. The clinical and prognostic 
value of SBPM is recognized by treatment guidelines,8,15,69 
and the technique is recommended by the National 
Institute of Clinical Excellence as an alternative to ABPM 
for confirming diagnosis of hypertension.8 SBPM is useful 
in diagnosing essential hypertension, white-coat hyperten-
sion, and refractory hypertension. In addition, it can be used 
to evaluate BP control and detect orthostatic hypotension in 
treated hypertensives. The technique also has the benefit of 
making patients more aware of their disease and CV risk, 
and may facilitate compliance with treatment.70
The prognostic value of SBPM on the occurrence of 
CV events has been well demonstrated.4 The SHEAF (Self-
measurement of BP at Home in the Elderly: Assessment and 
Follow-up) study, which included nearly 5000 hypertensive 
patients aged over 60, showed that the risk of CV events 
was doubled if the SBPM remained abnormal under treat-
ment, whereas the office BP was normalized.26 The study 
also   demonstrated that the CV morbimortality of treated 
hypertensive subjects suffering from masked hypertension 
was identical to that of treated but uncontrolled hypertensive 
subjects (both office measurement and SBPM), ie, triple that 
of subjects with normal BP.26
SBPM has the weakness of not capturing nocturnal BP 
and not allowing comparison of BP profiles between day and 
night, or analysis of the early morning BP surge. However, 
the technique can be used to capture daytime ambulatory BP 
and a greater number of readings can be taken than office 
monitoring, and in a more realistic setting, thus avoiding 
white-coat hypertension.70 Being less restrictive than ABPM, 
SBPM is better accepted by patients71,72 and is more acces-
sible to physicians.
For the technique to be effective, SBPM must follow a 
strict procedure (eg, sitting position, several minutes rest, 
correct cuff size) using validated tools, with priority to 
semiautomatic and brachial devices.15,69 Measurements must 
be made in the morning (before drug intake) and evening 
for several days in a row. When several measurements are 
made over several minutes, the results of the first one must 
not be taken into account because they are often higher than 
the others.69 Normal values of BP measured in SBPM are a 
systolic BP lower than 135 mmHg and a diastolic BP lower 
than 85 mmHg.15
Treatment of hypertension  
and evaluation of BP control
The 2009 reappraisal of European guidelines on hypertension 
management recommends lowering office systolic/diastolic 
BP to values within the range 130–139/80–85 mmHg, 
and possibly close to lower values in this range in all 
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  hypertensive patients.73 In the vast majority of patients, 
effective BP   control can only be achieved by combining at 
least two antihypertensive drugs.73 As recommended by the 
European guidelines, drugs that exert their antihypertensive 
effect over 24 hours with a once-a-day administration should 
be preferred because a simple treatment schedule promotes 
compliance.15
As discussed earlier in this review, ABPM and SBPM 
are valuable methods for verifying the BP lowering efficacy 
of antihypertensives over 24 hours. The effect of antihy-
pertensives is known to be greater on clinical BP than 
ambulatory BP,39 and the proportion of patients achieving 
satisfactory BP control may be different when BP is mea-
sured in the clinic or by ambulatory monitoring.26,74,75 For 
example, a study of 103 treated patients demonstrated that 
a large number of patients deemed to be controlled by office 
BP did not have adequate BP control based on ABPM.74 The 
SHEAF trial has added to the   complexity of hypertension 
control by showing that office readings were inaccurate in 
22% of treated hypertensive patients: 13% had uncontrolled 
clinic BP but controlled SBPM, and 9% had controlled 
clinic BP but uncontrolled SBPM.26 The shortfalls of clinic 
BP were also demonstrated in the AASK (African American 
Study of Kidney Disease and Hypertension) trial, in which 
the majority of subjects with controlled clinic BP were 
shown to have abnormal BP profiles including nondipping 
and/or reverse dipping, elevated nighttime BP, and masked 
hypertension.76 These studies urge caution when interpreting 
clinic BP measures and support a more systematic adoption 
of ABPM and SBPM within clinical practice.
Out-of-office versus clinic 
measurements: advantages  
and limitations
As discussed above, there is now convincing evidence that 
ABPM and SBPM provide more reliable BP measurements 
and are better predictors of CV complications and target 
organ damage than office measures. However, differences 
exist in their clinical benefits and limitations (Table 1). Cost 
and availability are major deciding factors for choice of 
BP measurement method; for example, the use of ABPM 
in   routine practice is often confined to high-risk patients 
or subjects with resistant hypertension due to the cost of 
devices and the need for personnel who are trained to use the 
devices and interpret the data. On the contrary, the increasing 
  availability of low-cost, accurate SBPM devices no longer 
limits their use in clinical practice. Whilst the implementation 
of ABPM within practice can be challenging, substantial 
benefits can be realized in terms of better targeting of treat-
ment and reduced healthcare costs.77
Conclusion
ABPM has broadened the horizons of hypertension research. 
The endorsement of ABPM by treatment guidelines and 
increasing awareness among physicians regarding the   benefits 
of this measure over traditional office measurements may 
lead to more accurate diagnosis, more appropriately targeted 
treatment, and improved clinical outcomes. This method of 
measuring BP gives more information than SBPM, but these 
two techniques are not mutually exclusive and both provide 
greater diagnostic and prognostic benefits than clinic BP 
measurements. Data from ABPM and SBPM enable accurate 
assessment of treatment effectiveness and thus may help tailor 
therapy for optimal BP management. With BP control rates 
remaining suboptimal, increased use of ABPM and SBPM 
for assessment of 24-hour control is warranted, especially in 
high-risk patients. Questions remain regarding the impact of 
ABPM and SBPM on clinical outcomes as the majority of 
existing data are from observational studies. Further clinical 
trials are needed, using ABPM and/or SBPM to evaluate pri-
mary outcomes of treatment efficacy and CV risk reduction. 
Additional research is also needed to obtain informa  tion about 
issues that remain unclear, such as the clinical importance of 
white-coat hypertension and ambulatory BP variability.
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